Characterizing the frequency of modifiable histological changes observed on surveillance biopsies in pediatric kidney allograft recipients.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
11 2020
Historique:
received: 21 01 2020
accepted: 19 05 2020
revised: 18 05 2020
pubmed: 20 6 2020
medline: 21 7 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

Rejection is responsible for just under 50% of graft loss in the pediatric kidney transplant population. Early identification and treatment of allograft injury, specifically modifiable pathologies such as subclinical rejection (SCR), calcineurin inhibitor toxicity, and BK virus nephropathy, may improve allograft survival. Protocol surveillance biopsy (SB) currently offers the earliest opportunity for targeted interventions. This is a single-center retrospective review of 215 kidney SBs obtained from 2008 to 2016 in 97 pediatric kidney transplant recipients. SBs were obtained at 6, 12, and 24 months post-transplantation. Frequency of abnormal histologic findings, estimated glomerular filtration rate at time of SB, and SB-related complications were recorded. Data were analyzed to investigate possible time trends and the presence of demographic or clinical associations with abnormal histologic findings. Potentially modifiable histologic findings were seen in 38.1% of all SBs. SCR was found with increasing frequency across all time points with an estimated 49% increase in the odds of a SCR finding per additional 6 months post-transplantation (aOR 1.49, 95% CI 1.06-2.09, p = 0.022). Among follow-up biopsies in patients who underwent treatment for SCR, 50% had no SCR and 18.8% showed histologic improvement. The complication rate associated with SB was 1.9% (4/215 SBs) and consisted of only minor complications. SBs are safe and offer the opportunity to identify and treat modifiable histologic changes in the pediatric kidney transplant population. The performance of SBs for up to 2 years after transplantation can have meaningful clinical impact.

Sections du résumé

BACKGROUND
Rejection is responsible for just under 50% of graft loss in the pediatric kidney transplant population. Early identification and treatment of allograft injury, specifically modifiable pathologies such as subclinical rejection (SCR), calcineurin inhibitor toxicity, and BK virus nephropathy, may improve allograft survival. Protocol surveillance biopsy (SB) currently offers the earliest opportunity for targeted interventions.
METHODS
This is a single-center retrospective review of 215 kidney SBs obtained from 2008 to 2016 in 97 pediatric kidney transplant recipients. SBs were obtained at 6, 12, and 24 months post-transplantation. Frequency of abnormal histologic findings, estimated glomerular filtration rate at time of SB, and SB-related complications were recorded. Data were analyzed to investigate possible time trends and the presence of demographic or clinical associations with abnormal histologic findings.
RESULTS
Potentially modifiable histologic findings were seen in 38.1% of all SBs. SCR was found with increasing frequency across all time points with an estimated 49% increase in the odds of a SCR finding per additional 6 months post-transplantation (aOR 1.49, 95% CI 1.06-2.09, p = 0.022). Among follow-up biopsies in patients who underwent treatment for SCR, 50% had no SCR and 18.8% showed histologic improvement. The complication rate associated with SB was 1.9% (4/215 SBs) and consisted of only minor complications.
CONCLUSIONS
SBs are safe and offer the opportunity to identify and treat modifiable histologic changes in the pediatric kidney transplant population. The performance of SBs for up to 2 years after transplantation can have meaningful clinical impact.

Identifiants

pubmed: 32556543
doi: 10.1007/s00467-020-04624-1
pii: 10.1007/s00467-020-04624-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2173-2182

Auteurs

James D Odum (JD)

Division of Graduate Medical Education, Children's Mercy Kansas City, Kansas City, MO, USA.

Alexander Kats (A)

Department of Pathology and Laboratory Medicine, Children's Mercy Kansas City, Kansas City, MO, USA.

Judith Sebestyen VanSickle (JS)

Division of Pediatric Nephrology, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.

Vimal Chadha (V)

Division of Pediatric Nephrology, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.

Brenda Brewer (B)

Division of Pediatric Nephrology, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.

Vincent S Staggs (VS)

Biostatistics & Epidemiology Core, Children's Mercy Kansas City, Kansas City, MO, USA.

Bradley A Warady (BA)

Division of Pediatric Nephrology, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA. bwarady@cmh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH